News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gyros AB Expands Commercial Reach in Asia


12/7/2011 10:33:53 AM

07 December 2011, Uppsala, Sweden: Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that Binex Co., Ltd., a leading CDMO (Contract Development & Manufacturing Organization) for biotechnology products in the Asian-Pacific region, has purchased a Gyrolab™ workstation.

S.E. Kim, president and CEO at DI Biotech, the sole distributor of Gyros products in South Korea, commented: “We are extremely pleased that Binex has become the first South Korean customer to adopt this exciting new platform. Our goal at DIBiotech is to ensure that our customers have access to the latest ground-breaking technologies. We firmly believe that the Gyros platform, will not only increase productivity, but also boost the competitiveness of South Korea’s pharma and biotech companies as well as our CROs and CMOs.”

The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, to boost time-critical workflows and help meet regulatory demands. The platform comprises a Gyrolab workstation, control and evaluation software and the unique microfluidic CDs in which immunoassay steps are integrated and run at nanoliter scale.

Erik Walldén, CEO at Gyros, continued, “We have been actively expanding our distributor network throughout the Asia-Pacific region and see this as a significant step on the way to establishing a global presence for our immunoassay platform.”

About Gyros AB www.gyros.com

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.

Enquiries:

Katie Odgaard

Zyme Communications Ltd

Tel: +44 (0) 7787 502 947

Skype: kodgaard

Email: katie.odgaard@zymecommunications.com

www.zymecommunications.com

Binex enquiries:

Jeong Hwa Son, Ph.D.

Binex Co., Ltd.

Songdo-dong 7-48, Incheon IFEZ, South Korea 406-840

Tel: +82-32-850-3121

Fax: +82-32-850-3128

Email: sjhwa@bi-nex.com

www.bi-nex.com


Read at BioSpace.com

comments powered by Disqus
Gyros AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES